What You Need to Know
• Medicare began covering obesity drugs for eligible beneficiaries at a cost of $50 per month starting in July.
• CVS and Walgreens reported filling around 100,000 prescriptions each for obesity medications within two months.
• The Bridge program allows Medicare coverage for certain conditions, excluding beneficiaries with sleep apnea or Type 2 diabetes.
Starting in July, Medicare Administrator Chiquita Brooks-LaSure announced that eligible beneficiaries can access obesity drugs, such as Wegovy, for $50 a month. Within two months, CVS Health Corporation and Walgreens Boots Alliance, Inc. reported filling approximately 100,000 prescriptions each under this new program. The Bridge program, designed as a pilot, allows Medicare to cover obesity medications if patients meet specific criteria, including having obesity along with difficult-to-control high blood pressure. However, beneficiaries with conditions like sleep apnea or Type 2 diabetes are not eligible, as Medicare Part D already covers GLP-1 drugs for those ailments. The program is set to continue through the end of 2027.
Why It Matters
This development is significant as it marks a shift in Medicare’s approach to obesity treatment, which has historically been limited. The Bridge program provides a workaround to existing regulations that prevent Medicare from covering weight loss drugs. With rising obesity rates in the United States, access to these medications could improve health outcomes for many individuals facing obesity-related health issues. The program’s success may influence future healthcare policies regarding obesity treatment and medication coverage.
Read the Full Story →
